CD38 inhibitors(Lymphocyte differentiation antigen CD38 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Antibody-dependent cellular phagocytosis (ADCP) effects

Therapeutic Areas

NeoplasmsImmune System DiseasesEndocrinology and Metabolic Disease+ [5]

Active Indication

Smoldering Multiple MyelomaImmunoglobulin Light-Chain AmyloidosisMultiple Myeloma+ [18]

Inactive Indication

Adult Lymphoblastic LymphomaB-cell lymphoma refractoryExtranodal NK-T-Cell Lymphoma+ [12]

Originator Organization

Janssen Global Services LLC

Active Organization

Xian-Janssen Pharmaceutical Ltd.Janssen Research & Development LLC

Janssen Pharmaceutica NV

+ [16]

Inactive Organization-

License Organization

Genmab A/S

Janssen Biotech, Inc.

Drug Highest PhaseApproved

First Approval Date

United States (16 Nov 2015),

Multiple Myeloma

RegulationBreakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Conditional marketing approval (China), Orphan Drug (Japan), Orphan Drug (South Korea), Orphan Drug (United Kingdom), Priority Review (Japan), Priority Review (China)

Structure/Sequence

Sequence Code 9075449L

Source: *****

Sequence Code 9946743H

Source: *****

341

Clinical Trials associated with Daratumumab

NCT06570915

/ Not yet recruitingPhase 2IIT

A Prospective, Single-arm, Multicenter, Open-label , Phase 2 Study to Evaluate Efficacy and Safety of the Daratumumab in T Cell Acute Lymphoblastic Leukemia With Minimal Residual-Positive After Standard Chemotherapy

T-ALL accounts for about 15%-25% of Ph-negative ALL, and its clinical prognosis is worse than B-ALL. The successful application of immunotherapy has brought revolutionary progress to the treatment of ALL. But progress in the treatment of T-ALL has been relatively slow. Minimal residual disease (MRD) is a strong prognostic indicator for ALL patients. MRD-positive after induction therapy predicts a high risk of relapse. The National Comprehensive Cancer Network (NCCN) considers MRD-positive ALL patients to be at high risk. Research in the B-ALL field has demonstrated that immunotherapy has the potential to further clear MRD, which in turn translates into survival benefits. Daratumumab is a humanized, anti-CD38 IgG1 monoclonal antibody that binds to CD38 expressed by tumor cells. Apoptosis of tumor cells is induced through a variety of immune-related mechanisms such as complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cytophagocytosis (ADCP), and FCγ receptors, which are currently mainly used in the treatment of multiple myeloma. CD38 is highly and stably expressed on the surface of T-ALL cells, and its expression was less influenced by the previous treatment. Preliminary data from the clinical study of daratumumab combined with BFM bone frame prescription for the treatment of recurrent refractory T ALL(NCT03384654) showed that the effectiveness rate (ORR) was 83.3% in children and 60% in young adults. Compared with the previous historical data, the safety and tolerability were significantly improved. For T-ALL patients who relapse after allogeneic transplantation and achieve CR with intense chemotherapy but continue to have MRD-positive flow rate, daratumumab monotherapy can further clear MRD and achieve the purpose of sustaining CR. These studies all demonstrate the potential role of daratumumab in the treatment of T-ALL. Based on the current difficulties in the treatment of T-ALL and existing research data, we plan to conduct a prospective, single-arm, open-label phase II clinical study to explore the efficacy and safety of daratumumab for flow minimal residual disease positive T-ALL after standard chemotherapy.

Start Date01 Dec 2025

Sponsor / Collaborator

Hematology Hospital of Chinese Academy of Medical Sciences

NCT07095452

/ Not yet recruitingPhase 2/3

Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. This is a study to determine the adverse events, change in disease activity, and pharmacokinetics of Etentamig in adult participants with MM.
Etentamig is an investigational drug being developed for the treatment of MM. This study is broken into 2 phases; phase 2 with 3 study arms and phase 3 with 2 study arms. Participants in phase 2 will receive 1 of 3 doses of etentamig in combination with daratumumab. Participants in phase 3 will receive etentamig at RP3D in combination with daratumumab, or daratumumab, lenalidomide, and dexamethasone (DRd). Around 660 adult participants with MM will be enrolled at approximately 155 sites worldwide
Participants in phase 2 will receive 1 of 3 doses of etentamig as intravenous (IV) infusions, combination with subcutaneous (SC) injections of daratumumab. Participants in phase 3 will receive RP3D doses of etentamig as IV infusions, combination with SC injections of daratumumab, or SC injections of daratumumab, capsules of lenalidomide, and tablet/ IV injections of dexamethasone (DRd). The study duration is approximately 16 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

Start Date12 Nov 2025

Sponsor / Collaborator

AbbVie, Inc.

NCT06948084

/ Not yet recruitingPhase 2IIT

A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)

This phase II trial compares the effect of the combination of daratumumab-hyaluronidase (daratumumab) and teclistamab to the usual treatment of daratumumab, pomalidomide, dexamethasone or daratumumab, carfilzomib and dexamethasone in treating patients with multiple myeloma that has not responded to previous treatment (refractory) or that has come back after a period of improvement (relapsed). Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Teclistamab is a bispecific antibody that can bind to two different antigens at the same time. Teclistamab binds to B-cell maturation antigen, a protein found on some B-cells and myeloma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Pomalidomide is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Carfilzomib, a type of proteasome inhibitor, blocks the action of enzymes called proteasomes, which may help keep cancer cells from growing and may kill them. Giving daratumumab and teclistamab may be more effective than the usual treatment of daratumumab, pomalidomide, dexamethasone or daratumumab, carfilzomib and dexamethasone in reducing myeloma cells to undetectable levels in patients with relapsed or refractory multiple myeloma.

Start Date31 Oct 2025

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Daratumumab

100 Translational Medicine associated with Daratumumab

100 Patents (Medical) associated with Daratumumab

2,096

Literatures (Medical) associated with Daratumumab

01 Jan 2026·BIOMATERIALS

CD38-targeted antibody-polymer drug conjugates for enhanced treatment of multiple myeloma

Article

Author: Li, Shannuo ; Al Faruque, Hasan ; Yang, Jiyuan ; Li, Jiahui ; Kopeček, Jindřich ; Sborov, Douglas W

Multiple myeloma (MM) remains a formidable disease, especially in relapsed or refractory cases when there are limited treatment options. In this study, we introduce two polymer-antibody drug conjugates (pADCs), ISA-P-EPI (U6244-021) and DARA-P-EPI (U6244-031), which contain semitelechelic N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-epirubicin (EPI) conjugate attached to CD38-targeting antibodies Isatuximab (ISA) and Daratumumab (DARA). These pADCs enhance therapeutic efficacy by combining the specificity of ISA and DARA with the cytotoxic potency of EPI while preserving antibody function. The EPI is linked to the HPMA polymer backbone via a tetrapeptide spacer cleavable by lysosomal enzymes, enabling drug release upon endocytosis within tumor cells. This design achieves a higher drug-to-antibody ratio than conventional ADCs for safer delivery of drug payload. In vitro studies demonstrate efficient binding, internalization, and cytotoxic efficacy of these pADCs in MM cell lines. Mechanistic investigations revealed significant therapeutic effects, including cell cycle arrest, immunogenic cell death, and preserved antibody-dependent cellular cytotoxicity (ADCC). In addition, pADCs were effective in 5 out of 8 primary samples, with their efficacy closely correlating with CD38 surface expression levels. To enhance therapeutic outcomes, we employed panobinostat to upregulate CD38 expression, which further improved pADC efficacy. In a preclinical NRG mouse model inoculated with MM.1S-luc cells, pADC treatment significantly delayed tumor progression and prolonged survival, with all treated mice remaining alive at the 100-day endpoint. These findings underscore the potential of CD38-targeted pADCs as a novel approach to combining chemotherapy with immunotherapy for MM treatment, warranting further investigation into their optimization and clinical application.

31 Dec 2025·ANNALS OF MEDICINE

Serum free light chain level-based and non-fixed cycle daratumumab treatment strategy for patients with light chain amyloidosis

Article

Author: Huang, Xianghua ; Guo, Jinzhou ; Chen, Wencui ; Li, Zhen ; Zhao, Liang ; Ren, Guisheng

BACKGROUND:

In recent years, daratumumab (DARA) has gained widespread use in the treatment of systemic light chain (AL) amyloidosis. In this study, we assessed the efficacy and safety of a DARA treatment strategy based on serum free light chain (sFLC) levels and non-fixed cycles.

METHODS:

The study included 123 patients with Al amyloidosis who received DARA at our center between July 2020 and September 2023. All patients received the standard DARA treatment (16 mg/kg weekly for four weeks) during the first course. Subsequent treatments were adjusted based on sFLC levels and the physician's judgment.

RESULTS:

The results demonstrated an impressive overall hematologic response rate (ORR) of 94.3%, with a hematologic very good partial response (VGPR) and complete response (CR) rate of 84.5%. Median time to best hematologic response was 1 months. Cardiac and renal response rates were 39.3% and 60.3%, respectively. Thirty patients experienced grade 1/2 infusion-related reactions after the first infusion. The rate of grade 3/4 adverse events was 21%. The most common adverse events of grade 3 or 4 were pulmonary infection (6.5%), neutropenia and lymphocytopenia (5.7%), elevated transaminases (1.6%), acute kidney injury (1.6%). After a median follow-up of 13 months (range 1-38), The 1-year OS and PFS estimates were 96.5% and 84.4%, respectively.

CONCLUSION:

These findings indicate that the sFLC levels based and non-fixed cycle DARA strategy is an efficacious and safe treatment strategy in both newly diagnosed and relapsed/refractory AL amyloidosis.

31 Dec 2025·ANNALS OF MEDICINE

Clinical outcome of ≥2% circulating tumor cells in newly diagnosed multiple myeloma: insights from a multicenter study

Article

Author: Liang, Dong ; Wang, Hua ; Xia, Zhongjun ; Feng, Yuan ; Yan, Yurong ; Jin, Fengyan ; Chen, Xiaoqin ; Zeng, Min ; Nie, Xiaomiao ; Bu, Yuying ; Bai, Shenrui ; Liang, Yang ; Wang, Qiaoli ; Xu, Weiling ; Feng, Demei

PURPOSE:

Previous studies have shown that ≥2% circulating tumor cells (CTCs) in multiple myeloma are associated with a prognosis similar to primary plasma cell leukemia. This study aims to examine this ultra-high-risk patient subset and evaluate their clinical outcomes in a real-world clinical setting.

METHODS:

We included 1,056 newly diagnosed multiple myeloma patients treated with novel agents. CTCs levels were determined via morphological assessment on peripheral blood smears, using a 2% cutoff to stratify patients into <2% and ≥2% CTCs groups. We then evaluated clinical outcomes across these groups.

RESULTS:

Patients with ≥2% CTCs constitute an ultra-high-risk subgroup, with outcomes resembling those of primary plasma cell leukemia. Survival outcomes improved for patients receiving daratumumab-based quadruplet therapy. Single autologous stem cell transplantation (ASCT) partially improved outcomes for patients with ≥2% CTCs. Achieving complete remission (CR) after induction treatment did not confer a better prognosis for this population. Furthermore, one high-risk cytogenetic abnormality (HRA) worsened outcomes in the <2% CTC group, while ≥2 HRA were associated with poorer outcomes in the ≥2% CTC group. Concurrent 1q21+ and other HRA further conferred a worse prognosis. In de novo extramedullary extraosseous (EME) multiple myeloma, defined as patients presenting with soft tissue or visceral plasmacytomas not connected to bone at initial diagnosis, ≥2% CTCs remained a strong predictor of poor prognosis.

CONCLUSION:

Our study suggests that patients with ≥2% CTCs represent a distinct ultra-high-risk subgroup in multiple myeloma and warrant separate consideration. VRD, IRD, DVRD, and DRD were reliable choices as frontline therapies for patients with <2% CTCs. Daratumumab-based quadruplet therapy may be a promising option for patients with ≥2% CTCs. Further research should continue to explore this specific aspect in greater depth.

589

News (Medical) associated with Daratumumab

25 Jul 2025

·pipelinereview.com

Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma

LONDON, UK I July 24, 2025 I GSK plc (LSE/NYSE: GSK) today announced the approval of Blenrep in the European Union (EU) for the treatment of adults with relapsed or refractory multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have received at least one prior therapy, and in combination with pomalidomide plus dexamethasone (BPd) in patients who have received at least one prior therapy including lenalidomide. The approval is based on superior efficacy results demonstrated by Blenrep combinations in the pivotal DREAMM-7 and DREAMM-8 phase III trials in relapsed or refractory multiple myeloma. These include statistically significant and clinically meaningful progression-free survival (PFS) for Blenrep combinations versus triplet standard of care combinations in both trials and overall survival (OS) versus a daratumumab-based triplet in DREAMM-7. 2,3,4 The safety and tolerability profiles of the Blenrep combinations were broadly consistent with the known profiles of the individual agents. 2,3 Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, sai d: “Today’s approval of Blenrep combinations is a redefining moment for patients with relapsed or refractory multiple myeloma in the EU. Blenrep has the potential to extend remission and survival, with superior efficacy versus standards of care in our DREAMM clinical trial programme and the option to administer in both academic and community-based settings.” More than 50,000 cases of multiple myeloma are diagnosed in Europe each year, accounting for more than a quarter of global incidence. 5 Blenrep is the only anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (ADC) approved in multiple myeloma, providing patients with a differentiated mechanism of action to potentially help slow disease progression and extend survival. 1 Blenrep combinations can be administered to a range of patient types across oncology treatment settings, enabling broad accessibility of an anti-BCMA therapy. María-Victoria Mateos, MD, PhD, Head of Myeloma and Clinical Trials Unit, Haematology Department and Professor of Medicine at the University of Salamanca, Spain, and DREAMM-7 principal investigator, said : “With the approval of Blenrep combinations in the EU, we now have additional tools in our efforts to keep patients in remission longer, maintain quality of life and extend survival. The robust efficacy supported by the DREAMM-7 and DREAMM-8 trials, together with manageable outpatient administration in academic and community settings, positions Blenrep combinations as a fundamentally differentiated treatment approach for multiple myeloma patients starting from first relapse.” Both DREAMM-7 and DREAMM-8 showed statistically significant and clinically meaningful PFS improvements for the Blenrep combinations compared to standard of care triplet combinations in the second line or later treatment of multiple myeloma. 2,3 In DREAMM-7, the Blenrep combination (n=243) nearly tripled median PFS versus the daratumumab-based comparator (n=251) (36.6 months versus 13.4 months, respectively (hazard ratio [HR]: 0.41 [95% confidence interval (CI): 0.31-0.53], p-value<0.00001). 2 DREAMM-7 also met the key secondary endpoint of OS, showing a statistically significant and clinically meaningful 42% reduction in the risk of death at a median follow-up of 39.4 months favouring the Blenrep combination versus the daratumumab-based comparator (HR: 0.58; 95% CI: 0.43-0.79; p=0.00023). The median OS was not reached in either arm of the study. The three-year OS rate was 74% in the Blenrep combination arm and 60% in the daratumumab combination arm. 4 In DREAMM-8, at a median follow-up of 21.8 months, the median PFS was not yet reached (95% CI: 20.6-not yet reached [NR]) with the Blenrep combination compared to 12.7 months in the bortezomib combination (95% CI: 9.1-18.5) at the time of primary analysis. 3 Blenrep combinations consistently benefited a broad range of patients, including those with poor prognostic features or outcomes, such as high-risk cytogenetics or those refractory to lenalidomide. Both trials also showed clinically meaningful improvements across all other secondary efficacy endpoints, including deeper and more durable responses versus the respective comparators. 2,3 DREAMM-7 and DREAMM-8 showed that eye-related side effects associated with Blenrep can be managed and reversed with appropriate dose modifications and follow-up. This allowed patients to maintain benefit and resulted in low rates of discontinuation due to eye-related side effects (≤9%) in both trials. 2,3 The most commonly reported non-ocular adverse events (>30% of participants) in the Blenrep combination arm were thrombocytopenia (87%) and diarrhoea (32%) in DREAMM-7, and neutropenia (63%), thrombocytopenia (55%) and COVID-19 (37%) in DREAMM-8. 2,3 Blenrep combinations are also approved in relapsed or refractory multiple myeloma in the UK 6 and Japan 7 as well as other markets, including Canada and Switzerland (based on the results of DREAMM-8). Applications are currently under review in all major markets globally, including the US 8 and China 9 (based on the results of DREAMM-7, with Breakthrough Therapy Designation for the combination and priority review for the application). About multiple myeloma Multiple myeloma is the third most common blood cancer globally and is generally considered treatable but not curable. 10,11 There are approximately more than 180,000 new cases of multiple myeloma diagnosed globally each year. 5 Research into new therapies is needed as multiple myeloma commonly becomes refractory to available treatments. 1 Many patients with multiple myeloma are treated in a community cancer setting, leaving an urgent need for new, effective therapies with manageable side effects that can be administered outside of an academic centre. 12,13 About Blenrep Blenrep is an ADC comprising a humanised BCMA monoclonal antibody conjugated to the cytotoxic agent auristatin F via a non-cleavable linker. The drug linker technology is licensed from Seagen Inc.; the monoclonal antibody is produced using POTELLIGENT Technology licensed from BioWa Inc., a member of the Kyowa Kirin Group. Indication In the EU, Blenrep is indicated in adults for the treatment of relapsed or refractory multiple myeloma: IMPORTANT SAFETY INFORMATION FOR BLENREP Refer to the Blenrep EMA Reference Information 14 which will soon be available for a full list of adverse events and the complete important safety information in the EU. About DREAMM-7 DREAMM-7 is a multicentre, open-label, randomised phase III clinical trial evaluating the efficacy and safety of belantamab mafodotin combined with bortezomib plus dexamethasone (BVd) compared to daratumumab combined with bortezomib plus dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma who previously were treated with at least one prior line of multiple myeloma therapy, with documented disease progression during or after their most recent therapy. The trial enrolled 494 participants who were randomised 1:1 to receive either BVd or DVd. Belantamab mafodotin was administered at a dose of 2.5mg/kg intravenously every three weeks in combination for the first eight cycles and then continued as a single agent. The primary endpoint was PFS as per an independent review committee, with secondary endpoints including OS, duration of response (DOR), and minimal residual disease (MRD) negativity rate as assessed by next-generation sequencing. Other secondary endpoints include overall response rate (ORR), safety, and patient reported and quality of life outcomes. PFS results were presented at the American Society of Clinical Oncology (ASCO) Plenary Series in February 2024 and published in the New England Journal of Medicine . OS results were presented at the American Society of Hematology (ASH) Annual Meeting in December 2024. 2,4 About DREAMM-8 DREAMM-8 is a multicentre, open-label, randomised phase III clinical trial evaluating the efficacy and safety of belantamab mafodotin in combination with pomalidomide plus dexamethasone (BPd) compared to bortezomib and pomalidomide plus dexamethasone (PVd) in patients with relapsed or refractory multiple myeloma previously treated with at least one prior line of multiple myeloma therapy, including a lenalidomide-containing regimen, and who have documented disease progression during or after their most recent therapy. The trial included 302 participants who were randomised 1:1 to receive either BPd or PVd. Compared to the patient population studied in the DREAMM-7 trial, patients in DREAMM-8 were more heavily pre-treated in that all had prior exposure to lenalidomide, 78% were refractory to lenalidomide, 25% had prior daratumumab exposure and of those most were daratumumab refractory. Belantamab mafodotin was administered at a dose of 2.5mg/kg intravenously for the first cycle and then 1.9mg/kg intravenously every four weeks. The primary endpoint was PFS as per an independent review committee, with key secondary endpoints including OS and MRD negativity rate as assessed by next-generation sequencing. Other secondary endpoints include ORR, DOR, safety, and patient reported and quality of life outcomes. Results were first presented at the 2024 ASCO Annual Meeting and published in the New England Journal of Medicine . 3 Updated PFS results were presented at the European Hematology Association (EHA) Congress in June 2025. 15 GSK in oncology Our ambition in oncology is to help increase overall quality of life, maximise survival and change the course of disease, expanding from our current focus on blood and women’s cancers into lung and gastrointestinal cancers, as well as other solid tumours. This includes accelerating priority programmes such as antibody-drug conjugates targeting B7-H3 and B7-H4, and IDRX-42, a highly selective KIT tyrosine kinase inhibitor. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. References SOURCE: GlaxoSmithKline

Clinical ResultPhase 3Drug ApprovalASCOBreakthrough Therapy

25 Jul 2025

·firstwordpharma.com

Sanofi’s Sarclisa closes in on J&J’s Darzalex with yet another myeloma approval in EU

Sanofi's anti-CD38 monoclonal antibody Sarclisa (isatuximab) bagged the European Commission’s approval for a fourth multiple myeloma (MM) indication, this time in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) for induction treatment of patients with newly diagnosed MM who are eligible for autologous stem cell transplant.With the latest clearance, the Sanofi antibody joins Johnson & Johnson's CD38 inhibitor Darzalex (daratumumab) as a treatment option for this patient population. “Today’s decision…paves the way for Sarclisa to potentially become accessible to even more patients in the EU, regardless of transplant eligibility or line of therapy,” commented Olivier Nataf, global head of oncology at Sanofi. The expanded approval is based on part one of the Phase III GMMG-HD7 study, which showed that Sarclisa plus VRd achieved the primary goal of minimal residual disease negativity following induction, alongside prolonged progression-free survival versus VRd alone.Earlier EU authorisations for Sarclisa include two indications in previously treated relapsed/refractory MM and one in transplant-ineligible patients with newly diagnosed MM. Meanwhile, Sanofi recently touted positive data for a subcutaneous (SC) formulation of Sarclisa, giving the drug a fair chance of disrupting Darzalex’s dominance (see – Spotlight On: J&J's Darzalex joins the $10 billion club) in the MM space. The latter’s SC version has been on the market since 2020 under the name Darzalex Faspro (daratumumab/hyaluronidase-fihj).

Drug ApprovalPhase 3Clinical ResultCell Therapy

25 Jul 2025

·pmlive.com

GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by the European Commission (EC) to treat adults with relapsed or refractory multiple myeloma . The drug has been authorised alongside bortezomib plus dexamethasone (BVd) to treat patients who have received at least one prior therapy, and in combination with pomalidomide plus dexamethasone (BPd) to treat those who have received at least one prior therapy including lenalidomide. More than 50,000 cases of multiple myeloma, a type of blood cancer that develops in plasma cells in the bone marrow, are diagnosed in Europe each year. While some patients may experience long remissions following treatment, most will eventually relapse. GSK’s Blenrep is the only B-cell maturation antigen-targeted antibody-drug conjugate approved for multiple myeloma, offering patients a differentiated mechanism of action. Blenrep combinations can also be given across oncology treatment settings without hospitalisation or complex pre-administration regimens. The EC’s decision was based on positive results from the late-stage DREAMM-7 and DREAMM-8 trials, which both demonstrated statistically significant and clinically meaningful progression-free survival (PFS) improvements for the Blenrep combinations compared to standard-of-care triplet combinations. In DREAMM-7, the Blenrep combination almost tripled median PFS versus the daratumumab-based comparator, at 36.6 months versus 13.4 months, respectively. In DREAMM-8, median PFS was not reached in the Blenrep cohort at a median follow-up of 21.8 months, compared to 12.7 months for the bortezomib combination. DREAMM-7 also met the key secondary endpoint of overall survival, and both trials showed clinically meaningful improvements across all other secondary efficacy endpoints, including deeper and more durable responses. Hesham Abdullah, senior vice president, global head oncology, research and development at GSK, described the approval as a “redefining moment for patients with relapsed or refractory multiple myeloma in the EU”. “Blenrep has the potential to extend remission and survival, with superior efficacy versus standards of care in our DREAMM clinical trial programme and the option to administer in both academic and community-based settings,” Abdullah added. DREAMM-7 principal investigator, María-Victoria Mateos, said: “The robust efficacy supported by the DREAMM-7 and DREAMM-8 trials, together with manageable outpatient administration in academic and community settings, positions Blenrep combinations as a fundamentally differentiated treatment approach for multiple myeloma patients starting from first relapse.”

Drug ApprovalClinical ResultClinical Study

100 Deals associated with Daratumumab

External Link

KEGG	Wiki	ATC	Drug Bank
D10777	Daratumumab	L01XC24	DB09331

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Smoldering Multiple Myeloma	European Union	Janssen-Cilag International NV	24 Jul 2025
Smoldering Multiple Myeloma	Iceland	Janssen-Cilag International NV	24 Jul 2025
Smoldering Multiple Myeloma	Liechtenstein	Janssen-Cilag International NV	24 Jul 2025
Smoldering Multiple Myeloma	Norway	Janssen-Cilag International NV	24 Jul 2025
Immunoglobulin Light-Chain Amyloidosis	European Union	Janssen-Cilag International NV	20 May 2016
Immunoglobulin Light-Chain Amyloidosis	Iceland	Janssen-Cilag International NV	20 May 2016
Immunoglobulin Light-Chain Amyloidosis	Liechtenstein	Janssen-Cilag International NV	20 May 2016
Immunoglobulin Light-Chain Amyloidosis	Norway	Janssen-Cilag International NV	20 May 2016
Multiple Myeloma	United States	Janssen Biotech, Inc.	16 Nov 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Residual Neoplasm	Phase 3	United States	Janssen Research & Development LLC	26 Apr 2019
Residual Neoplasm	Phase 3	Canada	Janssen Research & Development LLC	26 Apr 2019
Amyloidosis	Phase 3	United States	Janssen Research & Development LLC	10 Oct 2017
Amyloidosis	Phase 3	United States	Xian-Janssen Pharmaceutical Ltd.	10 Oct 2017
Amyloidosis	Phase 3	Japan	Janssen Research & Development LLC	10 Oct 2017
Amyloidosis	Phase 3	Japan	Xian-Janssen Pharmaceutical Ltd.	10 Oct 2017
Amyloidosis	Phase 3	Australia	Xian-Janssen Pharmaceutical Ltd.	10 Oct 2017
Amyloidosis	Phase 3	Australia	Janssen Research & Development LLC	10 Oct 2017
Amyloidosis	Phase 3	Belgium	Janssen Research & Development LLC	10 Oct 2017
Amyloidosis	Phase 3	Belgium	Xian-Janssen Pharmaceutical Ltd.	10 Oct 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03792620 (Pubmed)	Phase 2	Multiple Myeloma CD38	24	Daratumumab, Cyclophosphamide, Thalidomide, Dexamethasone	bivfugeyuk(nympicjbye) = zmlcnwcevb tuzylaiwmz (mcrqrswkgp, 68.3 - 98.7)	Positive	01 Aug 2025
NCT04230304 (CTgov)	Phase 2	Recurrent Chronic Lymphoid Leukemia \| Chronic lymphocytic leukaemia refractory \| Refractory Small Lymphocytic Lymphoma	8	Ibrutinib+Daratumumab	vdbyryqnej = tobtxzzupm lsgrrmstsl (rykvocknfo, otguspccuy - ekiovcedph) View more	-	01 Jul 2025
NCT03012880 (CTgov)	Phase 2	Multiple Myeloma	80	lenalidomide+ixazomib citrate+daratumumab+dexamethasone (Cohort A)	xjgrdkxsfr = javhunugtl ejqjfkykcg (vafhcwysbe, vwoumjmuko - fhakervvsw) View more	-	04 Jun 2025
				lenalidomide+ixazomib citrate+daratumumab+dexamethasone (Cohort B)	xjgrdkxsfr = zptzlvcicp ejqjfkykcg (vafhcwysbe, gaticukrmv - ucywhznepi) View more
ASCO2025	Not Applicable	Multiple Myeloma	804	Daratumumab	jrrqcbzppd(wfbyzmdubi) = jxcnmvpllq gnmxjzanwo (absadcdtea ) View more	Positive	30 May 2025
				Lenalidomide	jrrqcbzppd(wfbyzmdubi) = aixwmzezeo gnmxjzanwo (absadcdtea ) View more
NCT04661137 (phase 2b study of selinexor, ASCO2025)	Phase 2	Multiple Myeloma	28	Selinexor 80 mg + Carfilzomib 20 mg/m2 + Dexamethasone	itsrsfhann(xlhoouzzfl) = ufpkfniuur kuewqlnzra (mwovbuzlqq ) View more	Positive	30 May 2025
				Selinexor 60 mg + Pomalidomide 4 mg + Dexamethasone	itsrsfhann(xlhoouzzfl) = wwrxbijiad kuewqlnzra (mwovbuzlqq )
NCT04181827 (CARTITUDE-4, CTgov)	Phase 3	Relapse multiple myeloma \| Multiple Myeloma	419	daratumumab+pomalidomide+bortezomib+dexamethasone (DPd) (Arm A: Standard Therapy: PVd or DPd)	pnrwwgrqil(xueezoepbf) = zfidqbscbc mjnquzzfpw (clrebhzfpl, yuzltyzuxr - uymmkjwztw) View more	-	20 May 2025
				Autoleucel [Cilta-cel]+JNJ-68284528 (Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel]))	pnrwwgrqil(xueezoepbf) = nqlovgzuol mjnquzzfpw (clrebhzfpl, wyrtojnjvh - xcnusbsnhr) View more
PB3012 (EHA2025)	Not Applicable	Multiple Myeloma First line \| Second line \| Third line CD38	133	Daratumumab (1L group)	epdughldgg(uopnbtwida) = aholhaaoks ccvbjqebyp (lnrdaqwpfk ) View more	Positive	14 May 2025
				Daratumumab (2L group)	epdughldgg(uopnbtwida) = qdrdbkwrtq ccvbjqebyp (lnrdaqwpfk ) View more
PB3021 (EHA2025)	Not Applicable	Immunoglobulin Light-Chain Amyloidosis CD38	38	Dara-CyBorD	suwvhhkucv(ozpfwdvjpn) = juibgohruh araxqmpdkj (lcehtkfwqn ) View more	-	14 May 2025
				CyBorD	suwvhhkucv(ozpfwdvjpn) = nkhemnyxsc araxqmpdkj (lcehtkfwqn ) View more
NCT03697655 (PREDATOR-MRD, EHA2025)	Phase 2	Multiple Myeloma MRD-negative complete response	71	Daratumumab	txgseeewsy(navodkdssj) = cfngjnyeta qwduvypfbr (iwyxnmnuzu, not reached - not reached) View more	Positive	14 May 2025
				Daratumumab (Observation)	txgseeewsy(navodkdssj) = btjikcktzy qwduvypfbr (iwyxnmnuzu, 5.0 - not reached) View more
OSHO #89 (EHA2025)	Not Applicable	Multiple Myeloma HiR cytogenetics \| del17p \| t(4;14) ... View more	203	CD38-IMiD	qwvuseifjd(ptirixdyoo) = afjrggmmna noedhmjbph (larshhuqof )	Positive	14 May 2025
				CD38-PI	qwvuseifjd(ptirixdyoo) = enstvvylle noedhmjbph (larshhuqof )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis